- Home
- ULS vs ICLR Comparison
ULS vs ICLR Comparison
Compare ULS & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULS
- ICLR
- Stock Information
- Founded
- ULS 1894
- ICLR 1990
- Country
- ULS United States
- ICLR Ireland
- Employees
- ULS N/A
- ICLR N/A
- Industry
- ULS
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- Sector
- ULS
- ICLR Health Care
- Exchange
- ULS Nasdaq
- ICLR Nasdaq
- Market Cap
- ULS 15.8B
- ICLR 14.3B
- IPO Year
- ULS 2024
- ICLR 1998
- Fundamental
- Price
- ULS $87.37
- ICLR $166.15
- Analyst Decision
- ULS Hold
- ICLR Buy
- Analyst Count
- ULS 8
- ICLR 15
- Target Price
- ULS $78.75
- ICLR $211.36
- AVG Volume (30 Days)
- ULS 582.8K
- ICLR 984.4K
- Earning Date
- ULS 11-04-2025
- ICLR 10-22-2025
- Dividend Yield
- ULS 0.59%
- ICLR N/A
- EPS Growth
- ULS 10.58
- ICLR N/A
- EPS
- ULS 1.67
- ICLR 7.47
- Revenue
- ULS $3,003,000,000.00
- ICLR $8,102,602,000.00
- Revenue This Year
- ULS $6.79
- ICLR N/A
- Revenue Next Year
- ULS $6.23
- ICLR $0.89
- P/E Ratio
- ULS $52.52
- ICLR $21.87
- Revenue Growth
- ULS 6.68
- ICLR N/A
- 52 Week Low
- ULS $48.54
- ICLR $125.10
- 52 Week High
- ULS $91.95
- ICLR $228.29
- Technical
- Relative Strength Index (RSI)
- ULS 72.21
- ICLR 43.42
- Support Level
- ULS $84.17
- ICLR $155.00
- Resistance Level
- ULS $91.95
- ICLR $167.87
- Average True Range (ATR)
- ULS 2.40
- ICLR 6.44
- MACD
- ULS 0.43
- ICLR -1.26
- Stochastic Oscillator
- ULS 69.85
- ICLR 36.08
About ULS UL Solutions Inc.
UL Solutions is a global leader specializing in a broad range of product testing, inspection, and certification services. UL Solutions is the for-profit branch out of three organizations under the UL Enterprise. TIC operations make up nearly all of UL Solutions' total revenue and are composed of two segments: industrial and consumer. UL Solutions' remaining business includes software and advisory, which complements its core TIC offerings. The firm operates globally.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.